Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $558.12, for a total transaction of $5,581,200.00. Following the completion of the sale, the chief executive officer now owns 33,608 shares of the company's stock, valued at $18,757,296.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Thermo Fisher Scientific Trading Down 0.7 %
NYSE TMO opened at $551.74 on Friday. The firm has a market cap of $211.04 billion, a PE ratio of 34.59, a price-to-earnings-growth ratio of 3.70 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 52 week low of $437.26 and a 52 week high of $627.88. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The company has a 50 day moving average price of $593.95 and a 200 day moving average price of $583.63.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm had revenue of $10.60 billion during the quarter, compared to analyst estimates of $10.63 billion. During the same quarter in the prior year, the business posted $5.69 EPS. The business's revenue for the quarter was up .2% compared to the same quarter last year. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.69 EPS for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
Media Is Mocking Elon, But Wait Until They See This Demo
From Brownstone Research | Ad
Elon Musk believes his new AI product will be worth an incredible $9 trillion.
But the mainstream media is not buying it.
Click here to watch this demo and decide for yourself.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.78%.
Institutional Trading of Thermo Fisher Scientific
Institutional investors have recently bought and sold shares of the stock. Beaumont Financial Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 0.8% during the first quarter. Beaumont Financial Advisors LLC now owns 2,199 shares of the medical research company's stock worth $1,278,000 after buying an additional 17 shares during the period. Cedar Wealth Management LLC lifted its position in Thermo Fisher Scientific by 14.5% during the 1st quarter. Cedar Wealth Management LLC now owns 134 shares of the medical research company's stock worth $78,000 after acquiring an additional 17 shares during the period. Lafayette Investments Inc. increased its holdings in shares of Thermo Fisher Scientific by 2.1% in the second quarter. Lafayette Investments Inc. now owns 830 shares of the medical research company's stock valued at $459,000 after purchasing an additional 17 shares during the period. IFG Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 3.3% during the third quarter. IFG Advisors LLC now owns 532 shares of the medical research company's stock worth $329,000 after purchasing an additional 17 shares during the period. Finally, Patrick M Sweeney & Associates Inc. boosted its position in Thermo Fisher Scientific by 1.8% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,031 shares of the medical research company's stock valued at $570,000 after buying an additional 18 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on the company. Stephens started coverage on Thermo Fisher Scientific in a research note on Tuesday, October 1st. They set an "overweight" rating and a $680.00 target price on the stock. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating for the company in a research report on Thursday, October 24th. Bernstein Bank raised their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a "market perform" rating in a research note on Tuesday, October 22nd. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an "overweight" rating for the company in a research report on Thursday, October 24th. Finally, Bank of America lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a "buy" rating in a research note on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and a consensus target price of $649.33.
Get Our Latest Analysis on TMO
Thermo Fisher Scientific Company Profile
(
Get Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
